EasyManua.ls Logo

Edwards SAPIEN 3

Edwards SAPIEN 3
46 pages
To Next Page IconTo Next Page
To Next Page IconTo Next Page
To Previous Page IconTo Previous Page
To Previous Page IconTo Previous Page
Loading...
44
Additional QoL instruments
QoL was also measured using the visual analog scale (VAS) of the EuroQoL (EQ-5D) measure
and the SF-36 Health Status Questionnaire. The VAS is a self-assessment in which patients rate
their well-being on a scale from 0 to 100 where 0 is the worst state they can imagine and 100 is
the best state. SF-36 uses 36 questions to measure functional health and well-being from the
patient’s point of view and is generally reported in two summary scores on a scale from 0 to 100
which evaluate physical (the Physical Summary Score) and mental (the Mental Summary Score)
health, with higher scores representing better functional health and well-being. The results of the
VAS and SF-36 measures are presented in Tables 26 and 27, respectively.
Table 26: EQ-5D Visual Analog Scale (EP Population)
EQ-5D Visual Analog Scale
SAPIEN 3 Valve
PIIA-SAVR
All
TF
Non-TF
Baseline
60.3 ± 20.0
61.0 ± 19.8
55.1 ± 20.7
59.5 ± 20.5
30 days
74.0 ± 16.6
74.8 ± 16.6
68.5 ± 16.2
67.2 ± 19.5
1 year
74.4 ± 17.2
74.7 ± 17.1
71.8 ± 17.8
74.3 ± 16.7
Plusminus values are means ± SD.
Table 27: SF-36 Health Status Questionnaire Score (EP Population)
SF-36 Health Status
Questionnaire Score
SAPIEN 3 Valve
PIIA-SAVR
All
TF
Non-TF
Physical Component Score
Baseline
34.7±9.1
35.0±9.1
33.1±8.5
34.3±9.0
30 days
39.7±9.8
40.3±9.7
34.8±9.2
34.5±8.4
1 year
40.0±10.3
40.4±10.2
37.0±10.8
39.5±10.4
Mental Component Score
Baseline
48.0±11.8
48.1±11.8
47.0±12.3
48.0±12.3
30 days
51.8±10.6
52.3±10.4
47.8±11.3
45.5±13.3
1 year
52.5±10.7
52.7±10.8
50.7±10.1
52.0±11.3
Plusminus values are means ± SD.
REFERENCES
[1]
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for
transcatheter aortic valve implantation: the Valve Academic Research Consortium-2
consensus document (VARC-2). Eur J Cardiothorac Surg 2012;42:S45-60.
[2]
Imbens G. W. (2004) Nonparametric Estimation of Average Treatment Effects under
Exogeneity: A Review. The Review of Economics and Statistics, February 2004,
86(1): 429.
These products are manufactured and sold under one or more of the following US patent(s): US Patent
No. 6,214,054; 6,547,827; 6,908,481; 7,214,344; 7,530,253; 7,585,321; 7,780,723; 7,846,203; 7,895,876;
7,993,394; 8,057,540; 8,382,826; 8,591,575; 8,690,936; 8,790,387; 9,301,840 and 9,301,841 and
corresponding foreign patents. Additional patents are pending.

Table of Contents

Related product manuals